Clay Siegall received his doctorate in Genetics from George Washington University and a Bachelor of Science degree in Zoology from the University of Maryland. Clay Siegall co-founded Seattle Genetics in 1998 and currently serves as the company’s President, Chief Executive Officer, and Chairman of the Board of Directors. During the company’s establishment, cancer treatments were controlled by chemotherapy that could barely distinguish between killing cancer cells and normal cells. Clay wanted to improve the lives of people living with cancer through the development of targeted therapies to cater for unmet needs.
Clay Sieagall established Seattle Genetics on a scientific innovation basis along with meticulous research, drug development practice, and his zeal to assist others. Under his leadership, the company, Seattle Genetics, was able to build a diverse pipeline of antibody cancer therapies which include ADCETRIS (brentuximab vedotin) for cancer treatment. ADCETRIS is currently an international brand approved in over 65 nations.
Clay Siegall is also in charge of the Seattle Genetics capital-raising activities having secured over $675 million through private and public funding, in addition to the company’s first public offering in 2001. Clay Siegall previously served at the Bristol-Myers Squibb Pharmaceutical Research Institute for a six year period and prior to that, he worked with the National Cancer Institute, National Institutes of Health from 1988 to 1991. Clay is also a member of the Board of Directors of a private biotechnology firm-Alder Biopharmaceuticals. Clay Siegall is an author and has published over 70 books and also holds 15 patents.
Clay Siegall has led Seattle Genetics into multiple strategic licenses for the company’s ADC technology which include AbbVie, Genentech (Roche), Astellas, Pfizer, and GlaxoSmithKline which have collectively generated more than $350 million to this day. There are more than 20 ADCs in the clinical development that utilize the company’s technology across internal and partner programs. Clay says that an important component their business plan involves partnering with other industry leaders and innovators in oncology drug development. He adds that the company’s ADC collaborations have helped market their technology, allowing the company to place resources into new ideas and new approaches to help patients.
Mikhail Blagosklonny is a leading oncologist who is also a philanthropist and professor. Dr. Blagosklonny was previously a professor at the Roswell Park Cancer Institute of New York. He attended First Pavlov State Medical University of St. Petersburg and earned his M.D in internal medicine and his PhD in experimental medicine and cardiology. He was hired as the associate professor of medicine at New York Medical College in 2002. After his time as associate professor of medicine he became employed as a senior scientist at Ordway Research Institute and remained in that position until 2009. In 2009 he took the position of professor of oncology at Roswell Park Cancer Institute.Mikhail believes in treating people like regular people despite their financial situations and economic standing.
Dr. Blagosklonny focuses his training in the fields of oncology and anti-aging techniques. He has many published journals that highlight his work and studies in the anti-aging treatment field. He also focuses his research and studies on providing pain free or low pain treatment options for those suffering from various types of cancers.Throughout his studies, Dr. Mikhail Blagasklonny has been trying to create a way to treat people’s cancer without destroying the healthy cells in their bodies. He has been seeking alternative treatments that are not painful to the body while it is fighting the disease. Dr. Blagosklonny believes that through medical advancements and the creation of new technology and medicine that cancer will one day be easily treatable. He has hopes of it becoming a low cost treatment disease that everyone will be able to afford.
Dr. Mikhail Blagosklonny currently works for the Roswell Park Cancer Institute in Buffalo New York. He is a Russian scientist whose native home is St. Petersburg.In the early 2000’s Dr. Blagosklonny was working with a tumor treating drug called rapamycin. While working with rapamycin he realized that the characteristics of it that helped reduce the growth of tumors also had an anti-aging effect. He’s been asked by many if it is safe to take and he has replied that it is not safe not to take it. He feels as though this drugs anti-aging properties will help heal the body.Dr. Mikhail Blagosklonny is also an editor and chief of Oncotarget. Oncotarget was established by him and Dr. Andrei V. Gudkov. It is a peer reviewed open access medical journal that is updated weekly. The last edition of this journal will be published with article 30 of 2017.